AI technology is transforming the biopharma industry by significantly reducing the time, cost, and risk associated with drug development. This shift recalibrates how companies are valued, with AI-enabled assets showing a substantial increase in risk-adjusted net present value—from a modeled negative $238.5 million to a positive $356.5 million. Major companies like Eli Lilly are investing in proprietary AI systems and partnerships, creating competitive advantages and new revenue streams. While smaller biotechs can also benefit from advanced AI platforms, challenges remain, including regulatory, model, and data risks that could impact outcomes.
Eli Lilly announced acquisitions of Curevo Inc., LimmaTech Biologics AG, and Vaccine Company, Inc., investing up to $3.8 billion to enhance its infectious disease research and vaccine development. These deals align with Lilly's strategy to prevent di...
Eli Lilly announced it will acquire three vaccine developers—Curevo, LimmaTech Biologics AG, and Vaccine Company—in deals totaling up to $3.83 billion. This strategic move expands Lilly's focus into infectious disease prevention, complementing its ex...
Lilly has agreed to acquire Curevo Vaccine, a biotech firm developing a next-generation shingles vaccine called amezosvatein, designed to improve tolerability and increase vaccination rates. The deal could pay Curevo shareholders up to $1.5 billion, ...
Eli Lilly announced plans to acquire Curevo, LimmaTech Biologics, and Vaccine Company for a total of nearly $4 billion in cash. This move aims to expand Eli Lilly's research and development efforts into infectious diseases, focusing on preventing dis...
Eli Lilly announced agreements to acquire Curevo, LimmaTech Biologics, and Vaccine Company to expand its infectious disease research. These acquisitions focus on developing vaccines targeting viral and bacterial pathogens linked to long-term health r...
